Dystrophin deficiency, inhalational anesthetics, and rhabdomyolysis

H. Schmitt,Joachim W. Schmidt,T. Muenster
DOI: https://doi.org/10.1111/j.1460-9592.2006.02046.x
2007-01-01
Paediatric Anaesthesia
Abstract:SIR–I read with interest the report of a suspected case of malignant hyperthermia in a child with laminin alpha 2 (merosin) deficiency in the absence of a triggering agent (1). I have two concerns about the report. First I believe that the authors did not substantially support their diagnosis of malignant hyperthermia. Their scoring of the episode is on the high side (2), nor is their explanation for the lack of a very elevated CPK very strong, since despite the use of dantrolene, CPK continued to rise in the postoperative period. As their patient exhibited a primary muscle response, did the authors look for myoglobinuria? My second concern is the linking of the disease laminin alpha 2 (merosin) deficiency to malignant hyperthermia. This is a common mistake to causally link two very rare diseases just because they happened simultaneously. As this particular child had previous general anesthetics with no evidence of malignant hyperthermia, it is not reasonable to label all children with this disease susceptible to MH. James Mayhew Texas Tech Health Science Center, Anesthesiology, Lubbock, Texas, USA (email: rejfm@hotmail.com)
What problem does this paper attempt to address?